Piramal CEO Peter DeYoung (Credit: Piramal Pharma Solutions via Youtube)

In­di­an CD­MO Pi­ra­mal Phar­ma to up in vit­ro ca­pa­bil­i­ties at ex­ist­ing site

Dur­ing a typ­i­cal­ly qui­et hol­i­day break in biotech, Pi­ra­mal Phar­ma made some noise, and it’s start­ing off 2022 with yet an­oth­er big an­nounce­ment.

The CD­MO will in­vest mil­lions in­to cre­at­ing a high-through­put screen­ing fa­cil­i­ty that will en­hance the al­ready ex­ist­ing in vit­ro bi­ol­o­gy ca­pa­bil­i­ties at its Ahmed­abad, In­dia drug dis­cov­ery site. The new ex­pan­sion is sched­uled to go live in Q3 of this year, and cou­ple its bi­ol­o­gy ser­vices with chem­istry ca­pa­bil­i­ties al­ready in op­er­a­tion.

The in­vest­ment comes with the hopes of im­prov­ing Pi­ra­mal’s dis­cov­ery ser­vices for its cus­tomers, and speed­ing up the drug dis­cov­ery cy­cle times. It al­so will add new staffers, in hopes of eval­u­at­ing and screen­ing 1,000 com­pounds a week. The plat­forms will be used to tar­get G-pro­tein-cou­pled re­cep­tors (GPCRs) and ki­nase-tar­get­ed ther­a­pies among oth­ers.

“As­sist­ing cus­tomers in the dis­cov­ery process is syn­er­gis­tic with our ef­forts to be a pa­tient-cen­tric CD­MO,” CEO Pe­ter DeY­oung said in a state­ment. “With this in­vest­ment, we are en­hanc­ing our dis­cov­ery plat­form by adding new in vit­ro bi­ol­o­gy ser­vices to our ex­ist­ing ca­pa­bil­i­ties, mak­ing us a more in­te­grat­ed part­ner.”

At the end of March, Pi­ra­mal spent $106 mil­lion plus fu­ture mile­stones for the In­di­an pep­tide API mak­er Hem­mo Phar­ma­ceu­ti­cals. The move was con­sid­ered by the com­pa­ny to be a part of a larg­er push in­to con­tract work in on­col­o­gy and meta­bol­ic ther­a­pies, and came with a man­u­fac­tur­ing fa­cil­i­ty in Turb­he that can pro­duce more than 30 APIs and an R&D fa­cil­i­ty in Thane. The growth in ther­a­pies for rare dis­eases and or­phan drugs has al­so in­creased the need for pep­tides, DeY­oung has said.

At the end of De­cem­ber, In­di­an CD­MO Ya­pan Bio an­nounced that it had land­ed an in­vest­ment from Pi­ra­mal Phar­ma to help en­hance its man­u­fac­tur­ing arm.

Ya­pan pro­vides bi­o­log­ic and vac­cine scale-up and man­u­fac­tur­ing ser­vices, in­clud­ing RNA, DNA, re­com­bi­nant vac­cines, gene ther­a­pies and mon­o­clon­al an­ti­bod­ies. Pi­ra­mal has tak­en on a 27.78% stake in the com­pa­ny with the in­vest­ment. Its goal is to help Ya­pan keep up the quick pace of the rapid­ly ex­pand­ing CD­MO space, in part through Pi­ra­mal’s fill-fin­ish ser­vices.

In 2020, Pi­ra­mal’s par­ent com­pa­ny con­sol­i­dat­ed all of its phar­ma units un­der one Pi­ra­mal Phar­ma um­brel­la, and put $32 mil­lion in­to its Riverview, MI API plant, which boasts 25,000 square feet. It of­fered up 20% of the phar­ma busi­ness as a part of a stake sale, giv­ing the CD­MO $490 mil­lion cash. It al­so en­tered a joint ven­ture with Al­ler­gan to man­u­fac­ture the com­pa­ny’s eye health prod­ucts.

The In­di­an com­pa­ny re­cent­ly re­ceived recog­ni­tion at the Con­fed­er­a­tion of In­di­an In­dus­try awards, when its En­nore and Pi­tham­pur sites were rec­og­nized as star cham­pi­ons and chal­lengers.

Ed­i­tor’s Note: For more news and ex­clu­sive cov­er­age from the man­u­fac­tur­ing beat, sub­scribe to the End­points Man­u­fac­tur­ing week­ly re­port in your read­er pro­file.

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

Gold for adults, sil­ver for in­fants: Pfiz­er's Pre­vnar 2.0 head­ed to FDA months af­ter Mer­ck­'s green light

Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children in June.

Now, two months after Merck’s 15-valent Vaxneuvance won the FDA stamp of approval for kids, Pfizer is out with some late-stage data on its 20-valent shot for infants.

Known as Prevnar 20 for adults, Pfizer’s 20vPnC will head to the FDA by the end of this year for an approval request in infants, the Big Pharma said Friday morning. Discussions with the FDA will occur first and more late-stage pediatric trials are expected to read out soon, informing the regulatory pathway in other countries and regions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Senate Finance Committee Chair Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

Sen­ate Fi­nance Chair con­tin­ues his in­ves­ti­ga­tion in­to phar­ma tax­es with re­quests for Am­gen

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

Ab­bott pumps $450M+ in­to new Ire­land-based man­u­fac­tur­ing site project and hir­ing spree

As Ireland continues to see more investments and building projects from pharma companies, another contender is looking to place more investment in the Emerald Isle.

According to a report from The Irish Times on Friday, Abbott Laboratories is investing €440 million, or about $451 million, to build a new manufacturing plant in Kilkenny, located in the country’s southeast, to make more of its glucose monitors.

FDA ap­proves sec­ond in­di­ca­tion for As­traZeneca and Dai­ichi's En­her­tu in less than a week

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu scored its second approval in less than a week, this time for a subset of lung cancer patients.

Enhertu received accelerated approval on Thursday to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have already received a prior systemic therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

J&J to re­move talc prod­ucts from shelves world­wide, re­plac­ing with corn­starch-based port­fo­lio

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.

CSL is gathering its four business units under a unified brand identity strategy (Credit: CSL company site)

CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp

CSL is gathering its brands under the family name umbrella, renaming its vaccine and newly acquired nephrology specialty businesses with the parent initials.

CSL Seqirus and CSL Vifor join CSL Plasma and CSL Behring as the four now uniformly branded business units of the global biopharma. The Seqirus vaccine division was formed in 2015 with the combination of bioCSL and its purchase of Novartis’ flu vaccine business. CSL picked up Vifor Pharma late last year in an $11.7 billion deal for the nephrology, iron deficiency and cardio-renal drug developer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Pharma brands are trying to figure out new ways to better reach patients and doctors, but also measure results. (Credit: Shutterstock)

Do phar­ma TV and so­cial ads work? Phar­ma mar­ket­ing agen­cies adopt­ing new tech so­lu­tions to find out

It’s a timeworn advertising question — is my ad campaign working? In pharma, that can be an especially difficult question to answer in part because of privacy regulations, but also because the brands spend a lot of money on TV commercials where viewers can’t directly click on an ad.

Healthcare marketing services companies like Lasso and CMI Media Group are trying to change that with new measurement methods and partnerships that aim to get closer to patients’ and physicians’ actions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Corey McCann, Pear Therapeutics CEO

Pear Ther­a­peu­tics touts Q2 growth while scal­ing back full-year goals and chop­ping 9% of staff

Pear Therapeutics set some ambitious goals back in March, predicting a five-fold boost in revenue and a surge in new prescriptions for its digital therapeutics. Now the company is scaling back those estimates and chopping 9% of its workforce — an all-too-common occurrence in biotech lately.

CEO Corey McCann unveiled Pear’s Q2 numbers on Thursday, touting a 20% quarter-over-quarter revenue growth totaling $3.3 million. That’s more than double what the company made in Q2 2021, and McCann thinks the team could see a nearly four-fold jump in revenue this year, falling in the range of $14 million to $16 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.